Assessing the effectiveness of camrelizumab plus apatinib versus sorafenib for the treatment of primary liver cancer: a single-center retrospective study

Although the effectiveness of camrelizumab plus apatinib has been confirmed in a phase II clinical study, the efficacy of camrelizumab plus apatinib versus sorafenib for primary liver cancer (PLC) remains unverified. We retrospectively collected the data of 143 patients with PLC who received camreli...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Dongbo, Wang, Yichun, Chen, Xiangxun, Kang, Mei, Zhu, Liyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432548/
https://www.ncbi.nlm.nih.gov/pubmed/37587189
http://dx.doi.org/10.1038/s41598-023-40030-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432548/
https://www.ncbi.nlm.nih.gov/pubmed/37587189
http://dx.doi.org/10.1038/s41598-023-40030-x

Ejemplares similares